ID21979A - METHOD OF USING INHIBITORS-CYHOXOXIGAGE-2-INHIBITORS AS ANTI-ANGIOGENIC SUBSTANCE - Google Patents

METHOD OF USING INHIBITORS-CYHOXOXIGAGE-2-INHIBITORS AS ANTI-ANGIOGENIC SUBSTANCE

Info

Publication number
ID21979A
ID21979A IDW990379A ID990379A ID21979A ID 21979 A ID21979 A ID 21979A ID W990379 A IDW990379 A ID W990379A ID 990379 A ID990379 A ID 990379A ID 21979 A ID21979 A ID 21979A
Authority
ID
Indonesia
Prior art keywords
inhibitors
cyhoxoxigage
angiogenic substance
angiogenic
substance
Prior art date
Application number
IDW990379A
Other languages
Indonesian (id)
Inventor
Jamie L Masferrer
Amiram Raz
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of ID21979A publication Critical patent/ID21979A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
IDW990379A 1996-11-19 1997-11-19 METHOD OF USING INHIBITORS-CYHOXOXIGAGE-2-INHIBITORS AS ANTI-ANGIOGENIC SUBSTANCE ID21979A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3140496P 1996-11-19 1996-11-19

Publications (1)

Publication Number Publication Date
ID21979A true ID21979A (en) 1999-08-19

Family

ID=21859277

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW990379A ID21979A (en) 1996-11-19 1997-11-19 METHOD OF USING INHIBITORS-CYHOXOXIGAGE-2-INHIBITORS AS ANTI-ANGIOGENIC SUBSTANCE

Country Status (19)

Country Link
EP (1) EP0941080A2 (en)
JP (1) JP2001505564A (en)
KR (1) KR20000053362A (en)
CN (1) CN1247470A (en)
AU (1) AU730211B2 (en)
BR (1) BR9713522A (en)
CA (1) CA2270469C (en)
CZ (1) CZ176899A3 (en)
ID (1) ID21979A (en)
IL (1) IL129604A (en)
NO (1) NO992309D0 (en)
NZ (1) NZ335853A (en)
PL (2) PL194717B1 (en)
RO (1) RO118566B1 (en)
RU (1) RU2268716C2 (en)
SK (1) SK59999A3 (en)
TR (1) TR199901703T2 (en)
UA (1) UA70294C2 (en)
WO (1) WO1998022101A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515014B2 (en) 1995-06-02 2003-02-04 G. D. Searle & Co. Thiophene substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6512121B2 (en) 1998-09-14 2003-01-28 G.D. Searle & Co. Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors
US6887893B1 (en) 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US6833373B1 (en) 1998-12-23 2004-12-21 G.D. Searle & Co. Method of using an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US20030013739A1 (en) * 1998-12-23 2003-01-16 Pharmacia Corporation Methods of using a combination of cyclooxygenase-2 selective inhibitors and thalidomide for the treatment of neoplasia
BR9916536A (en) * 1998-12-23 2002-01-02 Searle & Co Method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and, combination
ATE306263T1 (en) * 1999-03-10 2005-10-15 Searle Llc COMPOSITIONS FOR ADMINISTRATION OF A CYCLOOXYGENASE-2 INHIBITOR TO ANIMALS
AU775305B2 (en) * 1999-07-29 2004-07-29 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamide and platin compound
AU6469401A (en) * 2000-05-19 2001-11-26 Serono Reproductive Biology In Pharmaceutically active compounds and methods of use
WO2002039958A2 (en) 2000-11-03 2002-05-23 Tularik Inc. Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
KR100686537B1 (en) * 2001-12-28 2007-02-27 씨제이 주식회사 Diaryl 1,2,4-triazole derivatives having excellent selectivity as inhibitors of cyclooxygenase-2
JP2006503812A (en) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination of an allosteric carboxyl matrix metalloproteinase-13 inhibitor with a selective cyclooxygenase-2 inhibitor that is not celecoxib or valdecoxib
KR100484525B1 (en) * 2002-10-15 2005-04-20 씨제이 주식회사 Isothiazole derivatives, processes for the preparation thereof, and pharmaceutical compositions containing the same
RU2316295C1 (en) * 2006-03-16 2008-02-10 Федеральное государственное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова Федерального агентства по здравоохранению и социальному развитию Conservative method for treating eye appendage and orbit hemangioma in children
AT504159A1 (en) * 2006-08-16 2008-03-15 Marlyn Nutraceuticals Inc USE OF PROTEASES
RU2475257C1 (en) * 2011-06-22 2013-02-20 Людмила Николаевна Третьяк Preparation for increasing organism adaptability to extreme conditions
GB2496135B (en) * 2011-11-01 2015-03-18 Valirx Plc Inhibitors of the interaction between a Src family kinase and an androgen receptor or estradiol receptor for treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0764644A1 (en) * 1993-01-15 1997-03-26 G.D. Searle & Co. Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a gastrointestinal condition
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
ES2141916T3 (en) * 1993-11-30 2000-04-01 Searle & Co SUBSTITUTED PIRAZOLIL-BENZENOSULPHONAMIDES FOR THE TREATMENT OF INFLAMMATION.
US5466823A (en) * 1993-11-30 1995-11-14 G.D. Searle & Co. Substituted pyrazolyl benzenesulfonamides
US5521213A (en) * 1994-08-29 1996-05-28 Merck Frosst Canada, Inc. Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
DE69529690T2 (en) * 1994-12-21 2003-11-13 Merck Frosst Canada & Co., Halifax DIARYL-2 (5H) -FUARANONE AS COX-2 INHIBITORS
US5691374A (en) * 1995-05-18 1997-11-25 Merck Frosst Canada Inc. Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors

Also Published As

Publication number Publication date
AU7298298A (en) 1998-06-10
PL333370A1 (en) 1999-12-06
CN1247470A (en) 2000-03-15
CA2270469C (en) 2007-04-10
BR9713522A (en) 2000-03-21
JP2001505564A (en) 2001-04-24
RO118566B1 (en) 2003-07-30
NZ335853A (en) 2002-02-01
RU2268716C2 (en) 2006-01-27
PL194717B1 (en) 2007-06-29
SK59999A3 (en) 2000-01-18
PL191793B1 (en) 2006-07-31
WO1998022101A2 (en) 1998-05-28
IL129604A0 (en) 2000-02-29
KR20000053362A (en) 2000-08-25
CZ176899A3 (en) 1999-10-13
IL129604A (en) 2004-08-31
EP0941080A2 (en) 1999-09-15
WO1998022101A3 (en) 1998-06-25
TR199901703T2 (en) 2000-07-21
CA2270469A1 (en) 1998-05-28
UA70294C2 (en) 2004-10-15
NO992309L (en) 1999-05-12
NO992309D0 (en) 1999-05-12
AU730211B2 (en) 2001-03-01

Similar Documents

Publication Publication Date Title
ID17411A (en) METHOD OF PREPARATION-OBJECTS OF ABSORPTION OBJECTS
DK1121192T3 (en) Method of homogenization
DK1085981T3 (en) Method of packaging
IS8368A (en) New method
FI965268A0 (en) Method for the preparation of polyhydric alcohols
ID21979A (en) METHOD OF USING INHIBITORS-CYHOXOXIGAGE-2-INHIBITORS AS ANTI-ANGIOGENIC SUBSTANCE
ID26990A (en) METHOD OF MAKING DIMETHYLNAFTALENA
DE69733883D1 (en) METHOD FOR THE ADDITION OF BORON COMPOUNDS
EE04154B1 (en) Method of preparation of omeprazole
DE69733962D1 (en) PLASMA-etching method
ID22098A (en) METHOD TO REMOVE CORETANS
ID20733A (en) METHOD OF MAKING BRUSH
DE69709695D1 (en) PAGE COMPOSITION METHOD
DK0987356T3 (en) Method of drawing
DK0874822T3 (en) New method of manufacture
DE69737237D1 (en) METHOD OF DRYING
ID18300A (en) METHOD OF PENEMPERAN
ID16838A (en) COMPOSITION OF DEKAFLUOROPENTANA
ID19540A (en) METHOD OF MAKING BENZOFENON DECREASES
ID17419A (en) COMPOSITION OF DEKAFLUOROPENTANA
ID17941A (en) METHOD OF THE APPLICATION OF MARKA JALAN MAKERS COMPOSITION
ID23019A (en) METHOD OF MAKING NITROGUADININ DOWN
ATE218559T1 (en) METHOD FOR THE MONOACYLATION OF HYDROXYTAXANES
EE9900404A (en) Method for the preparation of arylaminotriazolopyridines
BR9708484A (en) Application of substituted arylimidazoles